Abstract
This study suggested that immunization with rLong and rLong-∆G-EGFP were immunogenic and protected against RSV infection in the lower respiratory tract of BALB/c mice better than in the nose. Because of a relative low IgG1/IgG2a ratio, rLong-∆G-EGFP was more inclined to make CD4+ T cells, shifting toward a Th1-type response, indicating that the generation of a more balanced Th1/Th2 response was desirable. This explorative study on the recombinant Long viruses also contributed to obtaining more RSV attenuated candidates by a reverse genetics approach.
Introduction
Respiratory Syncytial Virus (RSV) remains a primary cause of severe respiratory infections in infants and the elderly. Despite decades of research, a licensed vaccine has been difficult to achieve, largely due to the legacy of the 1960s formalin-inactivated RSV (FI-RSV) vaccine. That vaccine resulted in "vaccine-enhanced disease," where natural infections became more severe in vaccinated children due to an imbalanced Th2-biased immune response and poor neutralizing antibody production.
To overcome these historical challenges, researchers are focusing on live-attenuated vaccines that mimic natural infection without causing disease. This requires precise molecular tools to manipulate the viral genome. This study details the development of a robust "reverse genetics" platform for the RSV Long strain, facilitating the design of safer, more effective vaccine candidates.
Methods and Viral Rescue
The researchers employed a multi-component reverse genetics approach to "rescue" infectious virus from synthetic DNA. The 15.2 kb RSV genome was assembled from six overlapping cDNA fragments into a specialized plasmid vector. To create a safer candidate, they engineered a mutant (rLong-ΔG-EGFP) by replacing the G glycoprotein gene—responsible for viral attachment—with an enhanced green fluorescent protein (EGFP) gene.
Viral rescue was achieved by co-transfecting Hep-2 cells with the full-length genome plasmid and four helper plasmids (encoding N, P, L, and M2-1 proteins). A helper vaccinia virus provided the T7 RNA polymerase necessary to initiate viral replication.
Key Results and Genetic Stability
Both the wild-type-like rLong and the mutant rLong-ΔG-EGFP were successfully recovered and remained genetically stable over nine passages in cell culture. While the removal of the G protein significantly weakened the virus—resulting in titers approximately 100-fold lower than the parental strain—the mutant remained highly immunogenic.
Correcting the Immune Bias
A critical finding of this study was the shift in the immune profile. In BALB/c mouse models, the rLong-ΔG-EGFP mutant elicited a lower IgG1/IgG2a antibody ratio compared to the wild-type recombinant. In murine immunology, this lower ratio signifies a shift toward a Th1-type response. This is a vital safety metric, as Th1 responses are associated with effective viral clearance and a significantly lower risk of the vaccine-enhanced respiratory disease seen in earlier FI-RSV trials.
Discussion and Future Directions
While the recombinant viruses provided 100% protection against viral replication in the lungs of mice, protection in the upper respiratory tract (the nasal passages) was less complete. This remains a common hurdle in RSV vaccine development, as mucosal immunity is notoriously difficult to maintain.
Furthermore, while the use of a helper vaccinia virus is a standard laboratory technique, it is cumbersome. Future iterations of this system may utilize cell lines that constitutively express T7 polymerase to streamline production. Despite these limitations, the successful establishment of this reverse genetics system for the RSV Long strain provides a powerful platform for developing and testing next-generation attenuated vaccine candidates.
Summary updated